Great progresses have been made towards expanding knowledge on cancer including how it is manifested, its various forms and treatment therapies. One of the leading success factors in regards to the fight against cancer is availability of information. The information gap when it comes to understanding cancer has been significantly reduced through various platforms including individual scientists who have excelled in researches on cancer and have shared their findings and expertise on numerous platforms including journals. Mikhail Blagosklonny is one such scientist who has played a significant role in expanding knowledge on cancer and aging through his exemplary researches. However, his revolutionary work extends beyond cancer and aging research; he sits on the editorial boards of several scientific and medicine journals dedicated to furthering knowledge on cancer and aging. The New York-based research scientist is also an author.
Scholarly Endeavors and Career Background
Mikhail Blagosklonny has a strong academic background in medicine having attended the prestigious First Pavlov State Medical University of St. Petersburg. He graduated with a Doctor of Medicine in internal medicine before returning to pursue his Doctor of Philosophy degree experimental medicine. He also specialized in cardiology for his PhD. In addition to his studies, he is also an author who has numerous articles including peer-reviewed research articles and book chapters to his name. His articles primarily focus on his areas of interest including oncology and aging.
In 2009, Mikhail Blagosklonny joined Park Cancer Institute as a professor specializing in oncology. He previously worked as a research scientist at Ordway Research Institute. In 2002, the New York Medical College appointed him as an associate professor. In addition to his current professorship duties, he is currently serving as an editor-in-chief of the weekly peer-reviewed journal, Oncotaget, which he co-founded. He also cofounded the biweekly and monthly journals Cell Cycle and Aging, respectively where also serves as a co-editor. Mikhail Blagosklonny has a long career as an editor for journals having also served as an editor for PLOS ONE, International Journal of Cancer, The American Journal of Pathology and Autophagy among others. View Mikhail’s profile on Google Scholar
Towards Greater Understanding of Cancer and Aging
Mikhail Blagosklonny is dedicated to unraveling the cloud of mystery that has always shrouded our understating of cancer. He is particularly interested in establishing the connection between aging process and cancer with the view of using anti-aging strategies as anticancer strategies. His revolutionary research work has focused on the role of target of rapamycin (TOR) in determining cell life cycle. The widely cited research established that TOR signaling delayed, inhibited or accelerated cell cycle processes such as autophagy, protein synthesis and apoptosis. Moreover, such delays in the onset of aging-related disorders and formation of cancerous cells as they fail to die off at the end of their life cycle. If TOR signaling can be regulated, the researcher believes that formation of some forms of cancers can thus be delayed or avoided.